InVision AI Cardiac Ultrasound Interpretation
AI-powered diagnosis of heart disease from ultrasound imaging
Software · OtherCompany source
Company profile
About InVision Medical Technology
InVision Medical Technology is a Y Combinator-backed startup (Summer 2022) that develops artificial intelligence solutions for diagnosing heart disease through automated ultrasound interpretation. The company addresses a critical challenge in cardiology: the 32 million heart ultrasounds performed annually in the United States are time-consuming, requiring over an hour of physician and technician time per exam, and suffer from considerable human-to-human variability that results in misdiagnosis and underdiagnosis. InVision's AI models have been tightly integrated into clinical workflows to enable easy usage by clinicians while improving diagnostic accuracy and efficiency. The company is leading the first and only blinded randomized trial of AI technology in cardiology, with results presented as a Late Breaking Clinical Trial at the European Society of Cardiology. InVision's work has been peer-reviewed and published in top medical venues including Nature (2020), Nature Medicine (2021), Lancet Digital Health (2021), and JAMA Cardiology (2022). The company is currently working on securing FDA clearance for its heart failure model and conducting clinical trials for models screening cardiac amyloidosis, hypertrophic cardiomyopathy, and aortic stenosis. InVision serves hospitals and health systems, with Cedars Sinai Medical Center as the first deployment site.
Company description InVision Medical Technology official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at InVision Medical Technology?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Aortic stenosis
- Cardiac amyloidosis
- Cardiac function evaluation
- Heart disease
- Heart failure
- Hypertrophic cardiomyopathy
Who it serves
- Health Systems
- Hospitals
- Medical device manufacturers
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsUnited States
Company sourceOfficial website
Company milestones
Platform expansion
Presented Late Breaking Clinical Trial at European Society of Cardiology. Working on FDA clearance for heart failure model. Starting clinical trials for cardiac amyloidosis, hypertrophic cardiomyopathy, and aortic stenosis screening models. Cedars Sinai Medical Center as first deployment site.
Partnerships
Recorded partners
- Cedars Sinai Medical Center
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
InVision Precision Cardiac AmyloidK243866 · 510k · May 21, 2025
InVision Precision LVEF (LVEF)K232331 · 510k · Apr 25, 2024
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Diagnostic accuracy improvement
Identifies diseases that may have been missed by human readers
Time efficiency
Streamlines interpretation of ultrasounds that typically require over an hour of physician and technician time
Reduced variability
Addresses human-to-human variability in ultrasound interpretation
Cedars Sinai Medical Center
First site of deployment for AI-powered cardiac ultrasound interpretation technology
Blinded randomized clinical trial results presented at European Society of Cardiology as Late Breaking Clinical Trial
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
David Ouyang
Co-Founder
Bryan He
Co-Founder
06 · Company updates
Updates from InVision Medical Technology
Recent articles published on InVision Medical Technology's official website.
Congratulations to EquipmentShare on Going Public
Read on InVision Medical TechnologyChristopher Golda and Grey Baker Join YC as General Partners
Read on InVision Medical TechnologyDiana Hu Is YC's Newest Managing Partner
Read on InVision Medical TechnologyCongratulations to Groww
Read on InVision Medical Technology07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.